|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 89.34 | 104.64 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1740.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | UnAudited | Net Sales | 1,269.90 | 1,537.00 | 1,535.80 | 1,477.80 | Total Expenditure | 1,062.70 | 1,158.00 | 1,162.90 | 1,155.40 | PBIDT (Excl OI) | 207.20 | 379.00 | 372.90 | 322.40 | Other Income | 16.50 | 19.20 | 18.30 | 18.10 | Operating Profit | 223.70 | 398.20 | 391.20 | 340.50 | Interest | 1.40 | 1.40 | 1.00 | 0.70 | Exceptional Items | 0 | 0 | 0 | 0 | PBDT | 222.30 | 396.80 | 390.20 | 339.80 | Depreciation | 44.90 | 41.40 | 42.30 | 42.10 | Profit Before Tax | 177.40 | 355.40 | 347.90 | 297.70 | Tax | 45.00 | 90.80 | 89.30 | 76.70 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 132.40 | 264.60 | 258.60 | 221.00 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 132.40 | 264.60 | 258.60 | 221.00 | Equity Capital | 132.30 | 132.30 | 132.30 | 132.30 | Face Value (IN RS) | 8 | 8 | 8 | 8 | Reserves | | | | | Calculated EPS | 8.01 | 16.00 | 15.64 | 13.36 | Calculated EPS (Annualised) | 32.02 | 64.00 | 62.55 | 53.45 | No of Public Share Holdings | 4,496,723.00 | 4,496,723.00 | 4,496,723.00 | 4,496,723.00 | % of Public Share Holdings | 27.19 | 27.19 | 27.19 | 27.19 | | | | | | PBIDTM% (Excl OI) | 16.32 | 24.66 | 24.28 | 21.82 | PBIDTM% | 17.62 | 25.91 | 25.47 | 23.04 | PBDTM% | 17.51 | 25.82 | 25.41 | 22.99 | PBTM% | 13.97 | 23.12 | 22.65 | 20.14 | PATM% | 10.43 | 17.22 | 16.84 | 14.95 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|